Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy

Lancet. 1988 Mar 26;1(8587):667-72. doi: 10.1016/s0140-6736(88)91475-4.


A phase I/II study of granulocyte colony stimulating factor (G-CSF) was undertaken in patients with advanced malignancy receiving melphalan to determine the granulocyte response, side-effects, and pharmacokinetics. Patients received doses of 1-60 micrograms/kg intravenously. There were 3 patients at each dose level. Before chemotherapy the immediate effect of G-CSF was a transient depression in circulating neutrophils followed by a dose-dependent rise. Neutrophil counts up to 80 X 10(9)/l were achieved. G-CSF administration following melphalan reduced the period of neutropenia caused by melphalan. G-CSF was well tolerated and the only clinical observation that appeared related to G-CSF administration was slight bone pain during some infusions. G-CSF was rapidly cleared from the blood with a mean half-life of 110 min for the second phase. Reductions in the number of days of neutropenia following cytotoxic chemotherapy may reduce the morbidity and mortality of chemotherapy.

MeSH terms

  • Aged
  • Agranulocytosis / drug therapy*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Colony-Stimulating Factors / administration & dosage
  • Colony-Stimulating Factors / pharmacokinetics
  • Colony-Stimulating Factors / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Evaluation
  • Granulocytes / drug effects*
  • Humans
  • Infusions, Intravenous
  • Leukocyte Count / drug effects
  • Male
  • Melphalan / administration & dosage
  • Melphalan / adverse effects
  • Middle Aged
  • Neutropenia / blood
  • Neutropenia / chemically induced
  • Neutropenia / drug therapy*
  • Neutrophils / drug effects
  • Time Factors


  • Antineoplastic Agents
  • Colony-Stimulating Factors
  • Melphalan